EA200501370A1 - Иммуномодулирующие гетероциклические соединения - Google Patents

Иммуномодулирующие гетероциклические соединения

Info

Publication number
EA200501370A1
EA200501370A1 EA200501370A EA200501370A EA200501370A1 EA 200501370 A1 EA200501370 A1 EA 200501370A1 EA 200501370 A EA200501370 A EA 200501370A EA 200501370 A EA200501370 A EA 200501370A EA 200501370 A1 EA200501370 A1 EA 200501370A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heterocyclic compounds
immunomodulating
immunomodulating heterocyclic
solvate
hydrate
Prior art date
Application number
EA200501370A
Other languages
English (en)
Other versions
EA009680B1 (ru
Inventor
Йен Ричард Мэтьюс
Original Assignee
Эвидекс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305876A external-priority patent/GB0305876D0/en
Priority claimed from GB0319429A external-priority patent/GB0319429D0/en
Application filed by Эвидекс Лимитед filed Critical Эвидекс Лимитед
Publication of EA200501370A1 publication Critical patent/EA200501370A1/ru
Publication of EA009680B1 publication Critical patent/EA009680B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Соединения формулы (I) являются ингибиторами CD80 и применимы в иммуномодулирующей терапиигде Rи Rнезависимо обозначают Н; F; Cl; Br; -NO, -CN; C-Салкил, необязательно замещённый F или Cl; или C-Салкокси, необязательно замещённый F;Rобозначает карбоксильную кислотную группу (-СООН) или её эфир, или -С(=O)NRRR, -NRC(=O)R, -N R-C(=O)OR, -NHC(=O)NRRили -NHC(=S)NRR, где Rобозначает Н или радикал формулы -(Alk)-Q, где m обозначает 0 или 1, Alk обозначает необязательно замещённый двухвалентный линейный или разветвлённый C-Cалкиленовый, или С-Cалкениленовый, или С-Cалкиниленовый радикал, или двухвалентный С-Скарбоциклический радикал, любой из этих радикалов может содержать одну или более -О-, -S- или -N(R)- связей, где Rобозначает Н или C-Cалкил, С-Cалкенил, С-Cалкинил, или С-Сциклоалкил, и Q обозначает Н; -NRR, где Rи Rнезависимо обозначают Н; C-Cалкил; С-Cалкенил; С-Cалкинил; С-Сциклоалкил; сложноэфирную группу; необязательно замещённую карбоциклическую или гетероциклическую группу; или Rи R, вместе с атомом азота, с которым они связаны, образуют цикл, который, необязательно, является замещённым; и Rобозначает Н или C-Салкил, или Rи R, вместе с атомом или атомами, с которым(-и) они связаны, образуют необязательно замещённый моноциклический гетероцикл, содержащий 5, 6 или 7 атомов в цикле; и Х обозначает связь или двухвалентный радикал формулы -(Z)-(Alk)- или -(Alk)- (Z)-, где Z обозначает -О-, -S- или -NH-, Alk имеет значение по определению для R, a n обозначает 0 или 1.
EA200501370A 2003-03-14 2004-03-10 Иммуномодулирующие гетероциклические соединения EA009680B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0305876A GB0305876D0 (en) 2003-03-14 2003-03-14 Immuno inhibitory heterocyclic compounds
GB0319429A GB0319429D0 (en) 2003-08-19 2003-08-19 Immuno Inhibitory Heterocyclic compounds
PCT/GB2004/001008 WO2004081011A1 (en) 2003-03-14 2004-03-10 Immunomodulating heterocyclic compounds

Publications (2)

Publication Number Publication Date
EA200501370A1 true EA200501370A1 (ru) 2006-08-25
EA009680B1 EA009680B1 (ru) 2008-02-28

Family

ID=32992598

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200702435A EA014080B1 (ru) 2003-03-14 2004-03-10 Иммуномодулирующие гетероциклические соединения
EA200501370A EA009680B1 (ru) 2003-03-14 2004-03-10 Иммуномодулирующие гетероциклические соединения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200702435A EA014080B1 (ru) 2003-03-14 2004-03-10 Иммуномодулирующие гетероциклические соединения

Country Status (20)

Country Link
US (3) US7276505B2 (ru)
EP (2) EP1603917B1 (ru)
JP (1) JP4892338B2 (ru)
KR (1) KR101133959B1 (ru)
AT (1) ATE489388T1 (ru)
BR (1) BRPI0408365B8 (ru)
CA (1) CA2519063C (ru)
DE (1) DE602004030225D1 (ru)
DK (1) DK1603917T3 (ru)
EA (2) EA014080B1 (ru)
EC (1) ECSP056104A (ru)
HK (1) HK1090921A1 (ru)
IL (1) IL170389A (ru)
MX (1) MXPA05009667A (ru)
NO (1) NO332136B1 (ru)
NZ (1) NZ541973A (ru)
PL (2) PL383655A1 (ru)
PT (1) PT1603917E (ru)
SI (1) SI1603917T1 (ru)
WO (1) WO2004081011A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4892338B2 (ja) 2003-03-14 2012-03-07 メディジーン アーゲー 免疫調節複素環化合物
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
PL1776366T3 (pl) * 2004-08-09 2009-06-30 Medigene Ag Immunomodulujące oksopirazolocynoliny jako inhibitory CD80
EP1912970A2 (en) * 2005-08-10 2008-04-23 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
GB0603522D0 (en) 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
MX2008011791A (es) 2006-03-15 2008-09-25 Wyeth Corp Azaciclilaminas-n-sustituidas como antagonistas de histamina-3.
WO2007136668A2 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
JPWO2008004610A1 (ja) * 2006-07-05 2009-12-03 国立大学法人 東京大学 ナンセンス変異型遺伝性疾患の治療方法
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
JP2010533725A (ja) 2007-07-16 2010-10-28 ワイス・エルエルシー ヒスタミン‐３（ｈ３）受容体としてのアミノアルキルアゾール化合物
EP2020404A1 (en) * 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2676666A1 (en) 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
AU2015315177A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
EP3558992A4 (en) 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. ACTIVATOR OF TREK (TWIK-ASSOCIATED K + CHANNELS) CHANNELS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629412A (en) 1946-12-24 1949-09-20 Geigy Ag J R Manufacture of metallisable monoazo dyestuffs of the pyrazolone series
US3576637A (en) 1967-04-20 1971-04-27 Konishiroku Photo Ind Lith-type of emulsion containing pyrozolone
JPS61161285A (ja) * 1984-12-28 1986-07-21 ルセル−ユクラフ ピラゾロ〔４，３−ｃ〕シンノリン−３−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物
US4591589A (en) * 1985-01-16 1986-05-27 Roussel Uclaf 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
DE3626221A1 (de) 1986-08-02 1988-02-04 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder
EP0269030B1 (en) 1986-11-20 1994-05-04 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor
DE3903993A1 (de) 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
ID16283A (id) * 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
GB9713707D0 (en) * 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
SE0102404D0 (sv) 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
EP1411052B1 (en) 2001-07-05 2011-10-05 Takeda Pharmaceutical Company Limited Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7081456B2 (en) 2002-11-22 2006-07-25 Active Biotech Ab Immunomodulatory compounds
DE60326639D1 (de) 2002-12-16 2009-04-23 Active Biotech Ab Tetrazyklische immunmodulierende verbindungen
JP4892338B2 (ja) * 2003-03-14 2012-03-07 メディジーン アーゲー 免疫調節複素環化合物
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
PL1776366T3 (pl) 2004-08-09 2009-06-30 Medigene Ag Immunomodulujące oksopirazolocynoliny jako inhibitory CD80
US20060221590A1 (en) * 2005-03-31 2006-10-05 Edoardo Campini System and method for Advanced Mezzanine Card connection
GB0603522D0 (en) 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition

Also Published As

Publication number Publication date
NZ541973A (en) 2009-06-26
EA009680B1 (ru) 2008-02-28
EA014080B1 (ru) 2010-08-30
US7276505B2 (en) 2007-10-02
PL383655A1 (pl) 2008-04-14
BRPI0408365B8 (pt) 2021-05-25
WO2004081011A1 (en) 2004-09-23
ECSP056104A (es) 2006-03-01
NO20054710D0 (no) 2005-10-13
MXPA05009667A (es) 2006-01-27
EP1603917B1 (en) 2010-11-24
IL170389A (en) 2013-08-29
US8309552B2 (en) 2012-11-13
CA2519063A1 (en) 2004-09-23
NO20054710L (no) 2005-12-13
PL1603917T3 (pl) 2011-12-30
DK1603917T3 (da) 2011-02-28
KR20050121681A (ko) 2005-12-27
NO332136B1 (no) 2012-07-02
EP1603917A1 (en) 2005-12-14
US20080045527A1 (en) 2008-02-21
CA2519063C (en) 2011-05-10
JP2006520372A (ja) 2006-09-07
EP2284172A1 (en) 2011-02-16
US7598247B2 (en) 2009-10-06
EA200702435A1 (ru) 2008-06-30
US20090312334A1 (en) 2009-12-17
DE602004030225D1 (de) 2011-01-05
HK1090921A1 (en) 2007-01-05
KR101133959B1 (ko) 2012-04-09
ATE489388T1 (de) 2010-12-15
US20070021428A1 (en) 2007-01-25
AU2004220310A1 (en) 2004-09-23
BRPI0408365A (pt) 2006-03-21
SI1603917T1 (sl) 2011-04-29
JP4892338B2 (ja) 2012-03-07
BRPI0408365B1 (pt) 2018-11-21
PT1603917E (pt) 2011-02-04

Similar Documents

Publication Publication Date Title
NO20054710L (no) Immunmodulerende heterosykliske forbindelser
NL300927I9 (nl) Tivozanib of een zout, solvaat of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
CY1107168T1 (el) Παραγωγα φαινυλοαλκανοϊκου οξεος και φαινυλοξυαλκανοϊκου οξεος ως ενεργοποιηται hppar
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
GB2398781B (en) Kinase inhibitors
IL165264A0 (en) Protein kinase inhibitors
SI1585739T1 (sl) Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
EA200801381A1 (ru) Производные пиримидина
NO20054669L (no) Substituerte kinobenzoxazinanaloger
HK1100659A1 (en) Hiv protease inhibiting compounds hiv
DE60319080D1 (de) Phenyloxyalkansäure-derivate als hppar aktivatore
MXPA05011276A (es) Derivado heterociclico de cinco miembros.
HK1086835A1 (en) N-[({'4-substituted piperazine-1-y}sulfonylmethyl)alkyl]-n-hxdroxyformamide compounds as metallopro teinase inhibitors
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen
TW200518748A (en) Chemical compounds
WO2004103305A3 (en) Spiropyrazole compound
DOP2002000354A (es) Compuestos farmaceuticamente activos.

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU